US FDA's data falsification rule raises industry concerns
This article was originally published in Clinica
Executive Summary
The US medtech industry has expressed serious concerns about a new rule proposed by the FDA, which, if finalised, would require device sponsors to report to the agency about any individual who is suspected of falsifying data in studies involving human or animal subjects.
You may also be interested in...
FDA Cancels Proposed Rule On Clinical Trial Malfeasance
US FDA has withdrawn a proposed rule that would have required sponsors to notify FDA if they became aware of data falsification during a clinical trial. Industry had been critical of the 2010 proposal.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.